These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
378 related articles for article (PubMed ID: 28185460)
1. [Daratumumab - Hope for Myeloma Patients, a Challenge for Clinical Laboratories]. Jelínek T; Kořístka M; Čermáková Z; Hájek R Klin Onkol; 2017; 30(1):13-19. PubMed ID: 28185460 [TBL] [Abstract][Full Text] [Related]
2. FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy. Bhatnagar V; Gormley NJ; Luo L; Shen YL; Sridhara R; Subramaniam S; Shen G; Ma L; Shord S; Goldberg KB; Farrell AT; McKee AE; Pazdur R Oncologist; 2017 Nov; 22(11):1347-1353. PubMed ID: 28904172 [TBL] [Abstract][Full Text] [Related]
3. Daratumumab for the treatment of multiple myeloma. Touzeau C; Moreau P Expert Opin Biol Ther; 2017 Jul; 17(7):887-893. PubMed ID: 28434255 [TBL] [Abstract][Full Text] [Related]
4. Daratumumab and its use in the treatment of relapsed and/or refractory multiple myeloma. Chehab S; Panjic EH; Gleason C; Lonial S; Nooka AK Future Oncol; 2018 Dec; 14(30):3111-3121. PubMed ID: 30136602 [TBL] [Abstract][Full Text] [Related]
5. Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab. Afifi S; Michael A; Lesokhin A Ann Pharmacother; 2016 Jul; 50(7):555-68. PubMed ID: 27083916 [TBL] [Abstract][Full Text] [Related]
6. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. Palumbo A; Chanan-Khan A; Weisel K; Nooka AK; Masszi T; Beksac M; Spicka I; Hungria V; Munder M; Mateos MV; Mark TM; Qi M; Schecter J; Amin H; Qin X; Deraedt W; Ahmadi T; Spencer A; Sonneveld P; N Engl J Med; 2016 Aug; 375(8):754-66. PubMed ID: 27557302 [